Inactive Instrument

News Interpace Biosciences, Inc. Other OTC

Stocks

IDXG

US46062X3035

Healthcare Facilities & Services

All News

05-12	Interpace Biosciences Announces First Quarter 2026 Financial and Business Results	AQ
05-12	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-30	Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results	AQ
03-30	Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-20	Interpace Biosciences Announces Preliminary and Unaudited Revenue Results for the Year 2025	CI
01-20	Interpace Biosciences, Inc. Provides Preliminary Unaudited Revenue Guidance for the Full Year of 2025 and Initiates Revenue Guidance for the Full Year of 2026	CI
01-20	Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure	AQ
12-03	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	CI
12-03	Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners	AQ
11-12	Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Interpace Biosciences Q3 revenue down	RE
11-12	Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results	AQ
25-09-16	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association Annual Meeting	AQ
25-09-15	Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting	AQ
25-08-07	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-07	Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results	AQ
25-05-08	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-05-08	Interpace Biosciences Announces First Quarter 2025 Financial and Business Results	AQ
25-05-08	Interpace Biosciences, Inc. Provides Revenue Guidance for the Full-Year 2025	CI
25-04-24	Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	AQ
25-03-31	Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-02-03	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results	AQ
25-01-31	Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results	AQ
25-01-27	PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan	AQ
25-01-09	Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk	CI